Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
Cancer Biomark. 2019;26(3):367-373. doi: 10.3233/CBM-190520.
BACKGROUND: Family with sequence similarity 83 member A (FAM83A) can promote tumor cell proliferation and facilitate epidermal growth factor tyrosine kinase inhibitor resistance in some malignant tumors, but its role in lung cancer has not been directly explored. OBJECTIVE: We investigated FAM83A expression in lung adenocarcinoma (LUAD) and its significance in clinicopathologic characteristics and prognosis of the disease. PATIENTS AND METHODS: We analyzed the mRNA expression of FAM83A in LUAD and normal (or adjacent) lung tissues from Oncomine database firstly. Then, we detected FAM83A protein expression in five paired fresh LUAD and adjacent lung tissue specimens from patients in our hospital by Western blotting. In addtion, FAM83A expression in 86 paraffin-embedded archived LUAD samples was evaluated by Immunohistochemistry, and the correlations between FAM83A expression and clinicopathologic characteristics and prognosis of the patients were analyzed. RESULTS: Oncomine data analysis manifested that FAM83A mRNA expression was increased in LUAD. Western blotting revealed higher FAM83A expression in fresh LUAD tissues than in the adjacent lung tissues (P= 0.036). Immunohistochemistry analysis on 86 paraffin samples further demonstrated that the LUAD tissue had higher FAM83A expression than adjacent lung tissue (P< 0.001). The correlation analysis revealed that advanced stage tumors (stage III-IV) had higher FAM83A expression than early stage tumors (stage I-II) (P= 0.004). High FAM83A expression was significantly associated with lymphnode involvement and clinical staging (P= 0.008 and 0.008 respectively). Univariate and multivariate Cox regression analysis manifested that FAM83A expression was an independent predictive factor for poor survival. Kaplan-Meier survival curves showed that patients with higher FAM83A expression had shorter overall survival than those with lower FAM83A expressions (P= 0.002). CONCLUSION: FAM83A is upregulated in advanced LUAD and is related to unfavorible prognosis. FAM83A might be a novel diagnostic and prognositic biomarker for LUAD.
背景：家族序列相似性 83 成员 A（FAM83A）可促进某些恶性肿瘤中的肿瘤细胞增殖并促进表皮生长因子酪氨酸激酶抑制剂耐药，但它在肺癌中的作用尚未被直接探索。
目的：我们研究了 FAM83A 在肺腺癌（LUAD）中的表达及其在疾病的临床病理特征和预后中的意义。
患者和方法：我们首先通过 Oncomine 数据库分析了 FAM83A 在 LUAD 和正常（或相邻）肺组织中的 mRNA 表达。然后，我们通过 Western blot 检测了来自我院的五对新鲜 LUAD 和相邻肺组织标本中 FAM83A 蛋白的表达。此外，通过免疫组织化学评估了 86 例石蜡包埋存档 LUAD 样本中 FAM83A 的表达，并分析了 FAM83A 表达与患者临床病理特征和预后的相关性。
结果：Oncomine 数据分析显示，FAM83A mRNA 在 LUAD 中表达增加。Western blot 显示新鲜 LUAD 组织中 FAM83A 表达高于相邻肺组织（P=0.036）。对 86 例石蜡样本的免疫组织化学分析进一步表明，LUAD 组织中 FAM83A 的表达高于相邻肺组织（P<0.001）。相关性分析显示，晚期肿瘤（III-IV 期）的 FAM83A 表达高于早期肿瘤（I-II 期）（P=0.004）。高 FAM83A 表达与淋巴结受累和临床分期显著相关（P=0.008 和 0.008）。单因素和多因素 Cox 回归分析表明，FAM83A 表达是不良预后的独立预测因素。Kaplan-Meier 生存曲线显示，FAM83A 表达较高的患者总生存期短于 FAM83A 表达较低的患者（P=0.002）。
结论：FAM83A 在晚期 LUAD 中上调，并与不良预后相关。FAM83A 可能是 LUAD 的一种新的诊断和预后生物标志物。
DNA Cell Biol. 2020-4-13
Int Immunopharmacol. 2019-12-5
Comput Math Methods Med. 2021
Zotero 插件